As a leading provider of Chimeric Antigen Receptor (CAR) field, Creative Biolabs provides CellRapeutics™ VHH-based CAR construction service according to diverse needs in different scientific projects. VHH-based chimeric receptor is considered as the fourth generation of CAR, which has been successfully studied in cancer targeting researches.
A figure adapted from Meyer et al., 2014.
De Meyer T, Muyldermans S, Depicker A. VHH-based products as research and diagnostic tools. Trends Biotechnol. 2014 May;32(5):263-70.
A figure from In Vivo Cellular and Molecular Imaging Brussels (ICMI Brussels), Vrije Universiteit Brussel.
VHH (Nb) is the variable domain of heavy-chain antibodies (also as known as VHH). It is the smallest antibody fragment with complete function. Generally, it only has half the molecular weight of a single-chain variable fragment (scFv), which is able to trigger an immune response. The advantage of Nb is its lower immunogenicity and better pharmacokinetics as a result of its small size and high affinity to target antigen. VHH-based conjugates such as Nb-enzyme, Nb-exotoxin or Nb-T cell are becoming potential strategies applied in tumor targeting treatment.
Technically, we can generate an Nb gene library derived from lymphocytes of camels, and then screen this Nb library with tumor associated antigens. After isolating the specific Nb, we will construct CAR-T cells with this specific-Nb (VHH-based CAR) instead of a scFv, which is different from classical CAR. Furthermore, we can also generate humanized camelid Nb according to your specific needs.
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved